Diversified Healthcare Trust (DHC) Q3 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call highlights positive financial performance with increased revenues, NOI, and occupancy across various segments. Despite temporary labor cost increases, the company maintains strong guidance and expects favorable transitions. The Q&A section reveals management's confidence in achieving targets and mitigating risks. The increase in SHOP NOI guidance and active disposition pipeline further support a positive outlook. However, the lack of specific details on potential revenue disruptions and disposition delays warrants caution. Overall, the sentiment leans towards positive due to strong financial metrics and optimistic guidance.
Key Financial Performance
Total Revenue $388.7 million, an increase of 4% year-over-year. The increase reflects continued momentum across operating segments and steady execution on initiatives to strengthen DHC's financial position.
Adjusted EBITDAre $62.9 million. No year-over-year change or reasons for change were mentioned.
Normalized FFO $9.7 million or $0.04 per share. No year-over-year change or reasons for change were mentioned.
SHOP Occupancy Increased 210 basis points year-over-year to 81.5%. The increase reflects the fourth consecutive quarter of occupancy growth.
RevPOR (Revenue Per Occupied Room) Rose 5.3% year-over-year. The increase is attributed to annual rate increases, gains in care level pricing, and reduced discounts and concessions at higher occupied communities.
ExpensePOR (Expense Per Occupied Room) Increased by 5.1% year-over-year. The increase is primarily driven by temporary labor cost increases associated with community transitions, wage adjustments, and filling of previously opened positions.
SHOP Revenues Increased 6.9% year-over-year. The increase is due to higher occupancy and RevPOR.
Consolidated SHOP NOI Increased 7.8% year-over-year to $29.6 million. The increase is attributed to higher occupancy and RevPOR, despite temporary labor cost increases.
Medical Office and Life Science Portfolio Occupancy Increased 370 basis points sequentially to 86.6%. The increase is primarily driven by asset sales of vacant or low occupancy properties and leasing during the quarter.
Same-Property Cash Basis NOI (Medical Office and Life Science Portfolio) Increased 1.6% year-over-year. Margins improved by 100 basis points to 58.9%. No specific reasons for the increase were mentioned.
Same-Property SHOP NOI Increased 6.6% year-over-year. The increase is due to improvements in occupancy and average monthly rate.
Same-Property SHOP Occupancy Increased 140 basis points year-over-year. The increase reflects positive momentum in occupancy.
Same-Property SHOP Average Monthly Rate Increased 5.3% year-over-year. The increase is attributed to pricing momentum.
Net Debt-to-Adjusted EBITDAre 10x, reflecting temporary compensation expense increases from the SHOP segment. Excluding $5.1 million of elevated compensation expenses, leverage would have been 9.3x, an improvement of 70 basis points.
Operating Highlights
Transition of AlerisLife-managed communities: DHC is transitioning 116 AlerisLife-managed communities to new operators, with 85 already transitioned. This is part of AlerisLife's wind-down strategy. The transition is expected to be completed by year-end 2025.
SHOP portfolio performance: SHOP occupancy increased 210 basis points year-over-year to 81.5%, marking the fourth consecutive quarter of growth. RevPOR rose 5.3%, and SHOP revenues increased by 6.9% year-over-year.
Medical Office and Life Science portfolio leasing: 86,000 square feet of leasing completed at weighted average rents 9% above prior rents. Consolidated occupancy increased 370 basis points to 86.6%.
Asset sales and proceeds: Year-to-date, DHC sold 44 properties for $396 million and has agreements to sell 38 more properties for $237 million. These sales will improve occupancy, margins, and cash flow.
Labor costs during transition: Temporary labor costs increased by $5.1 million due to the transition of AlerisLife communities, driven by operational support and employee overlap.
Capital investments: $43 million invested in Q3, including $35 million in SHOP communities and $7 million in Medical Office and Life Science portfolio. Incremental NOI of $2.8 million achieved from completed projects.
Debt refinancing and liquidity: DHC refinanced $1 billion for Vertex Pharmaceuticals' headquarters and issued $375 million in senior secured notes. The company plans to repay its 2026 bonds by year-end, leaving no maturities until 2028.
Geographic alignment strategy: Transitioning to a geographically aligned operating model with new 10-year operating agreements for SHOP communities, incorporating performance-based incentives.
Risk or Challenges
Elevated labor costs: The transition of 116 AlerisLife communities to new operators has led to elevated labor costs, including payroll allocation for property tours, community reviews, training, onboarding, and temporary employee overlap. This has resulted in an incremental cost of $5.1 million for the quarter.
Temporary decline in NOI: The transition of senior housing operating portfolio has caused a temporary decline in net operating income (NOI) due to increased labor costs and operational adjustments.
Debt leverage: Net debt-to-adjusted EBITDAre is currently high at 10x, reflecting elevated compensation expenses. Even excluding these expenses, leverage remains high at 9.3x, posing financial risk.
Asset sales dependency: The company is heavily reliant on asset sales to repay debt and improve liquidity. Delays or challenges in completing these sales could impact financial stability.
Occupancy and revenue risks: While SHOP occupancy and revenue have shown improvement, they remain below industry averages, and there is uncertainty about achieving consistent growth.
Transition execution risks: The transition of 116 communities to new operators involves operational complexities and risks, including potential disruptions in service quality and delays in achieving expected efficiencies.
Regulatory and compliance risks: The transition and new operating agreements may face regulatory scrutiny or compliance challenges, which could delay or complicate execution.
Interest rate and refinancing risks: The company has issued $375 million of 5-year secured bonds at a fixed coupon of 7.25%. Rising interest rates or unfavorable refinancing conditions could increase financial strain.
Guidance & Outlook
SHOP NOI guidance: Reaffirmed 2025 SHOP NOI guidance range of $132 million to $142 million.
Medical Office and Life Science portfolio: 1.5% of annualized revenue is scheduled to expire through year-end 2025, with 22,000 square feet expected to vacate. Active leasing pipeline totals 717,000 square feet, including 103,000 square feet of new absorption, with average lease terms of 7.6 years and GAAP rent spreads averaging more than 8%.
Capital markets and balance sheet initiatives: DHC plans to repay all amounts on January 2026 bonds as early as year-end, with no debt maturities until 2028. Asset sales of 38 properties for $237 million are expected to close by Q1 2026, reducing capital spending and improving cash flow.
SHOP segment performance: Expect improvements in adjusted EBITDAre with a full year 2025 range of $275 million to $285 million, trending towards positive cash flow as SHOP operations stabilize and leverage declines.
Transition of AlerisLife communities: All 116 communities are expected to transition to new operators by year-end 2025, with anticipated improvements in occupancy rates and NOI margins to align with industry averages.
Shareholder Return Plan
The selected topic was not discussed during the call.
Key Q&A
Earnings Word Cloud
DHC Transcript
The earnings call highlights positive financial performance with increased revenues, NOI, and occupancy across various segments. Despite temporary labor cost increases, the company maintains strong guidance and expects favorable transitions. The Q&A section reveals management's confidence in achieving targets and mitigating risks. The increase in SHOP NOI guidance and active disposition pipeline further support a positive outlook. However, the lack of specific details on potential revenue disruptions and disposition delays warrants caution. Overall, the sentiment leans towards positive due to strong financial metrics and optimistic guidance.
The earnings call highlights strong financial performance with a 3% revenue increase and a significant 172% FFO growth, driven by operational improvements. Despite high interest rates on new financing, the company's asset sales and debt management strategies are positive. The Q&A reveals strategic asset dispositions and gradual occupancy growth, with no major negative trends. The reaffirmed guidance and improved debt metrics indicate stability. Overall, the sentiment is positive, suggesting a potential stock price increase of 2% to 8% over the next two weeks.
The earnings call presents a mixed sentiment. Financial performance is strong with revenue and EBITDA growth, but guidance is weak, particularly in SHOP results. The market strategy shows proactive debt management and asset sales, but reduced CapEx limits growth. Shareholder returns focus on deleveraging, with uncertain future dividends. Q&A reveals some positive occupancy trends but also highlights uncertainties in guidance and future dividends. Overall, the sentiment is balanced, leading to a neutral prediction for stock price movement.
The earnings call summary presents mixed signals. Financial performance shows improvement with increased revenues and NOI, but concerns about debt maturities, regulatory issues, and competitive pressures persist. The lack of guidance increase and absence of a share repurchase or dividend program are notable downsides. The Q&A section highlights management's uncertainty about future guidance, which could affect investor sentiment. Overall, the company's financial health is improving, but uncertainties and lack of clear positive catalysts lead to a neutral outlook.
DHC Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
